At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 327 enrolled
Drug / intervention
AS012 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Randomized, Double Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of AS012 in Subjects With Non-segmental Vitiligo
In Brief
A Phase 2 clinical trial evaluating AS012 and Placebo for Non-segmental Vitiligo. Completed, enrolled 327 participants across 31 sites in 2 countries.
Detailed Summary
This is a randomized, double blind, placebo-controlled, phase II study. The study will be performed as a multicenter, multinational study.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-segmental Vitiligo
CountriesIndia, United States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedJul 2020
Enrollment StartJan 2021
Primary CompletionMay 2022
Study CompletionFeb 2023
TodayJul 2026
First PostedJul 27, 2020
Enrollment StartJan 13, 2021
Primary CompletionMay 20, 2022
Study CompletionFeb 27, 2023
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 5.9 years ago
Interventions
AS012drug
oral administration
Placebodrug
oral administration